Genprex Inc
Company Profile
Business description
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex’s oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company’s lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
Contact
3300 Bee Cave Road
Suite 650-227
AustinTX78746
USAT: +1 877 774-4679
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
25
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,471.50 | 18.80 | 0.22% |
CAC 40 | 7,282.69 | 10.37 | 0.14% |
DAX 40 | 19,848.77 | 35.98 | -0.18% |
Dow JONES (US) | 43,297.03 | 390.08 | 0.91% |
FTSE 100 | 8,136.99 | 34.27 | 0.42% |
HKSE | 20,098.29 | 215.16 | 1.08% |
NASDAQ | 20,031.13 | 266.24 | 1.35% |
Nikkei 225 | 39,568.06 | 437.63 | 1.12% |
NZX 50 Index | 13,074.74 | 86.71 | 0.67% |
S&P 500 | 6,040.04 | 65.97 | 1.10% |
S&P/ASX 200 | 8,220.90 | 19.30 | 0.24% |
SSE Composite Index | 3,393.53 | 42.27 | 1.26% |